Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + oxaliplatin + prednisolone
- Development stage
- Unknown
- Lead developer
- Asan Medical Center
- Modality
- Small Molecules
- Administration
- Intravenous, Oral
01
Overview
gemcitabine + oxaliplatin + prednisolone (GEMOX-P) is a combination chemotherapy regimen developed and investigated by Asan Medical Center for the treatment of metastatic castration-resistant prostate cancer (mCRPC), specifically in patients who have failed prior docetaxel therapy. The regimen consists of gemcitabine, a nucleoside analog that inhibits DNA synthesis and ribonucleotide reductase; oxaliplatin, a platinum-based agent that induces DNA cross-linking and apoptosis; and prednisolone, a corticosteroid that provides anti-inflammatory effects and may enhance the anti-tumor activity of the chemotherapy. This combination was evaluated in a Phase II clinical trial (NCT01487720) to assess its efficacy, safety, and impact on prostate-specific antigen (PSA) levels in the docetaxel-refractory setting.
- Other names
- GEMOX plus prednisoloneGEMOX-P
02
Targets
DNAGR (Glucocorticoid receptor)RNR (Ribonucleotide reductase)
Beyond the preview
Go deeper on gemcitabine + oxaliplatin + prednisolone.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + oxaliplatin + prednisolone.